Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112353 · ClinicalTrials.gov registry record · Phase 4
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
A Phase 4 study of Intestinal Disease, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
- 1
- Study location
NCT06112353 is a Phase 4 study of Intestinal Disease that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 128 participants, below the 195-participant average among 3 other Intestinal Disease trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06112353, a Phase 4 study of Intestinal Disease, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
Conditions Studied
Interventions
- DRUG Neostigmine Injectable Solution
- DRUG Sugammadex injection
Study Locations (1)
California
- UC Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06112353
The ClinicalTrials.gov registry entry for NCT06112353 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 3 other Intestinal Disease trials with a reported enrollment target (34% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intestinal Disease appearing as the primary indexed condition, and to 2 interventions - of which Neostigmine Injectable Solution is the first listed.
NCT06112353 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06112353 about?
NCT06112353 is a clinical study titled "Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection". The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
What is the current status of trial NCT06112353?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2024-04-17. Estimated completion is 2026-07-31.
What conditions does trial NCT06112353 study?
This clinical trial studies the following conditions: Intestinal Disease.
What interventions are being tested in trial NCT06112353?
The interventions under investigation include: Neostigmine Injectable Solution (DRUG), Sugammadex injection (DRUG).
Who is sponsoring clinical trial NCT06112353?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112353 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intestinal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.